



# JAMMU AND KASHMIR MEDICAL SUPPLIES CORPORATION LTD.

(Public Sector Undertaking of Govt of Jammu & Kashmir)  
Plot No 58, Friends Colony, Marble Market, Trikuta Nagar, Jammu  
Corporate Office Kashmir: 121, Green Avenue, Hyderpora, Opp. Al-Farooq Masjid, Srinagar  
Telephone: 0191-2580842, Fax: 0191-2581845 (Jammu); Telefax: 0194-2432008 (Srinagar)

**Subject:** Blacklisting /Debarring order in favour of M/s Lifemax Cancer Laboratories, Bhagirath Place, Chandni Chowk, Near Chandni Chowk Metro Station, Gate No. 5, New Delhi-110006.

**ORDER NO:** 65 -JKMSCL of 2025  
**DATED:** 21 /08/2025

Whereas, e-bid(s) for the finalization of Rate Contract for the Procurement of Allopathic Drugs/Medicines were issued by JKMSCL vide NIT No. JKMSCL/DRUGS & MEDICINES/2023-2024/592 dated 28/07/2023 & JKMSCL/DRUGS & MEDICINES/2023-2024/613 dated 05/02/2024 and M/s Lifemax Cancer Laboratories submitted the bid(s) against these NITs on 16-09-2023 & 19-03-2024 respectively;

Whereas, after following due procedure, the Rate Contracts of the following items were approved in favour of the firm:

S.No.	Name of Item	RC No. & Date	Approved Rates (inclusive of Taxes)
<b>Items approved against NIT No. JKMSCL/Drugs and medicines/2023-24/592 dated 28-07-2023</b>			
1	Tab. Vitamin-C 500mg (Chewing Tablet) [EDC03]	JKMSCL/GM(Drugs)/ 592/19297-02 Dated 30-01-2024	0.47
2	Cap. Gabapentitine 300 Mg [EDL1189A]	JKMSCL/GM(Drugs)/ 592/19297-02 Dated 30-01-2024	1.03
3	Tab. Montelukast 10mg [EDL977]	JKMSCL/GM(Drugs)/ 592/19297-02 Dated 30-01-2024	0.60
4	Tab. Olmesartan 20mg [EDL1061]	JKMSCL/GM(Drugs)/ 592/19297-02 Dated 30-01-2024	0.59
<b>Items approved against NIT No. JKMSCL/Drugs and Medicines/2023-24/613 dated 05.02.2024</b>			
5	Cap. Dutasteride Ip 0.50 Mg [EDL0134]	JKMSCL/GM(Drugs)/ 613/370-76 / 06- Feb-2025	0.45
6	Cap. Rifampicin Ip 450mg [EDL0211]	JKMSCL/GM(Drugs)/ 613/370-76 / 06- Feb-2025	3.58
7	Cap. Tamsulosin Ip 0.4 Mg [828]	JKMSCL/GM(Drugs)/ 613/370-76 / 06- Feb-2025	0.35
8	Tab. Betahistine Ip 24mg [EDL0181]	JKMSCL/GM(Drugs)/ 613/370-76 / 06- Feb-2025	0.38
9	Tab. Carbimazole Ip 10mg [EDL0159]	JKMSCL/GM(Drugs)/ 613/370-76 / 06- Feb-2025	0.50
10	Tab. Carbimazole Ip 5 Mg [624]	JKMSCL/GM(Drugs)/ 613/370-76 / 06- Feb-2025	0.34
11	Tab. Chlorothalidone Ip 6.25 Mg [1800]	JKMSCL/GM(Drugs)/ 613/370-76 / 06- Feb-2025	0.21
12	Tab. Dexamethasone Ip 4mg [EDL0052]	JKMSCL/GM(Drugs)/ 613/370-76 / 06- Feb-2025	0.39

S.No.	Name of Item	RC No. & Date	Approved Rates (inclusive of Taxes)
13	Tab. Dexamethasone Ip 8mg [EDL0027]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.63
14	Tab. Diltiazem Ip 120mg [EDL0095]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	1.20
15	Tab. Gliclazide Ip 40mg [EDL601]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.50
16	Tab. Gliclazide Ip 60mg [EDL0147]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.66
17	Tab. Gliclazide Ip 80mg [EDL0148]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.82
18	Tab. Isoniazid Ip 100mg [EDL0206]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.35
19	Tab. Isoniazid Ip 300mg [EDL0207]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.65
20	Tab. Letrozole Ip 2.5mg [EDL0225]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.58
21	Tab. Misoprostol Ip 25 Mcg, 1 Tab Pack [1140]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.39
22	Tab. Norethisterone Ip 5 Mg [621]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.28
23	Tab. Ornidazole Ip 500mg [1022]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.92
24	Tab. Prednisolone Ip 20mg [121]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	1.01
25	Tab. Propranolol Ip 40mg [451]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.26
26	Tab. Pyridoxine Ip 40mg Hcl [809]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.29
27	Tab. Sildenafil Ip 100mg Citrate [EDL0247]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.49
28	Tab. Sildenafil Ip 25mg Citrate [EDL0245]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.27
29	Tab. Sildenafil Ip 50mg Citrate [EDL0246]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.35
30	Tab. Tamsulosin 0.4 Mg [EDL0135]	JKMSCL/GM(Drugs)/ 613/370-76 / 06-Feb-2025	0.21

Whereas, it has come to the notice of JKMSCL that the firm stands blacklisted by Central Medical services Society (An Autonomous body under Ministry of Health & FW, Govt. of India) Chanakyapuri; New Delhi on 11-10-2023;

Whereas, the firm despite being blacklisted by Central Medical services Society (An Autonomous body under Ministry of Health & FW, Govt. of India) Chanakyapuri on 11-10-2023, continued to participate in the tenders floated by JKMSCL without informing about the blacklisting;

Whereas, the firm had submitted the affidavit(s) duly attested by Public Notary and undertakes as under:



- That neither our Firm nor our directors and officers stand blacklisted /debarred or banned/convicted by Bid Inviting Authority or Govt. of Jammu and Kashmir or any state Govt. or Govt. of India or its enterprise on the date of bid submission on the ground of submission of fake or forged documents or false information/facts, or for supply of drugs/medicines in India.
- That I/We has/have furnished the correct information in the tender and I/We shall be solely responsible and liable for punitive action for wrong/false information if found to have been submitted in the tender apart from forfeiture of EMD & performance security.
- I am/ We are aware of Tender Inviting Authority's right to forfeit the Earnest Money Deposit and/ or Security Deposit and blacklisting me/us for a period of 3 years in case, any information furnished by us proved to be false at the time of inspection or otherwise and not complying the conditions as per GMP Guidelines.
- I UMANG CHHABRA S/o LT SH B.N CHHABRA (Designation) Prop/ INSTITUTIONAL BUSINESS COORDINATOR/ Director of Firm M/s LIFEMAX CANCER LABAORATORIES Address PLOT NO 106 & 106 A SECTOR 6A IIE SIDCUL HARIDWAR 249403 Affirm on oath that the contents/information from para 1 to 16 as mentioned above, are true & correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if any information furnished by me as above is found wrong, false, forged or fabricated; the Corporation will be at liberty to cancel the Bid and forfeiting the earnest money deposit and or performance security, for which I shall be solely responsible and the laboratory / firm may be Debarred/Banned/ prosecuted for the same.

Whereas, the suppression of facts falls under clause 7.34.1.2 "Fraudulent practice" and other relevant clauses of SPP are mentioned as under:

6.2.7 The bidders who have been blacklisted/debarred by Tender Inviting Authority or blacklisted/debarred by any State Government or Central Government Organization for the reasons of quality non compliances, GMP non-compliances, major violation of the Drugs and Cosmetics act 1940(as amended from time to time), furnishing forged /fabricated /fake documents, should not participate in the tender during the period of blacklisting/debarring. Their bids if submitted shall not be considered.

6.2.8 where a product(s)/ supplier is blacklisted / debarred in any other state or by central Govt. agency for reasons as detailed in preceding clause occur after the submission/ opening of the bid/ award of contract, the product(s) /bidder will be liable for blacklisting /rejection / termination / cancellation of the contract / purchase order / LOI or any other action as deemed fit. The product(s) bidder will be liable for such action in the event of any conviction/ initiation of prosecution action under the Drugs and Cosmetics Act 1940 at any stage after submission/opening of bid.

7.34.1.2 "Fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of the Tender Inviting Authority, and includes collusive practice among bidders (prior to or after tender submission) designed to establish tender prices at artificial non competitive levels and to deprive the Tender Inviting Authority of the benefits of free and open competition. Suppression of facts such as blacklisting of the product/bidder elsewhere for reason of failure in quality / conviction under Drugs & Cosmetics act/declaration of more than 2



*batches of the product quoted as NSQ in the current/previous years shall be deemed as fraudulent practices. Making false/incorrect statements shall also be treated as fraudulent practice.*

Whereas, the matter was placed before the Disciplinary Committee in its meeting held on 21-05-2025 and the committee after deliberations decided to serve a show cause notice against the firm for seeking explanation in the matter, that why the firm did not inform JKMSCL regarding their blacklisting by Central Medical services Society (An Autonomous body under Ministry of Health & FW, Govt. of India) Chanakyapuri; New Delhi on 11-10-2023 as well as false / wrong declarations submitted to JKMSCL in the bid document.

Whereas, a show cause notice was served upon the firm vide this office No: JKMSCL/GM/DISC/2025-26/2019-26 dated 31-05-2025 with directions to explain the position within 07 days and in response the firm submitted its reply on 03-06-2025, which was again placed before the Disciplinary Committee in its meeting held on 14-06-2025, and after thorough deliberations, the Committee found that the response of firm was not in consonance with the terms & conditions of the NIT:

Whereas, the firm had undertaken under Annexure-D of NIT, Para3. (a) that:

*"We do hereby undertake that our company/firm has not been black listed/banned/debarred by Union Govt. or any State Govt. or their subordinate departments from participation in bidding"*

Whereas, point 3 (b) of the Annexure-D provides option for disclosing any facts about blacklisting of the firm/ product as under:

*We do hereby declare that our company/firm has been black listed/banned/debarred by..... (Name of Govt./Deptt.) and detailed information is as given below:*

- (i.) Cause of black listing/banning/Debarring.
- (ii.) For which item.....:
- (iii.) Period of black listing/banning/Debarring.
- (iv.) Latest Status of black listing/banning/Debarring.

Whereas, it is evident from the above that the firm was under an obligation to inform this office about your blacklisting by the Central Medical Services Society, including the reasons for such blacklisting and all relevant details, which the firm deliberately failed to disclose in order to participate in the bid; and

Whereas, at this stage, the firm cannot evade the responsibilities by claiming that they have not been blacklisted for submitting fake or forged documents, providing false information or facts, or for the supply of drugs/ medicines in India;

Whereas, it is evident from the reply that the firm was fully aware of blacklisting by the Central Medical Services Society and in order to secure the contract for the supply of drugs/ medicines, the firm submitted a false and misleading statement;

Whereas, another Show Cause Notice was issued against the firm vide No. JKMSCL/DISC/2025-26/54-61 dated 18.06.2025 wherein a final opportunity was given



to the firm to explain its position within 07 days and in response the firm submitted its reply on 25-06-2025 through e-mail, which was placed before the Disciplinary Committee in its meeting held on 01-08-2025 for taking final decision in the matter;

Whereas, the committee after examining the reply of M/s Life Max Cancer Laboratories is of the opinion that the reply is not satisfactory and since the firm concealed the facts regarding blacklisting at the time of submission of bids and also submitted the false undertakings, the committee decided to blacklist the firm M/s Life Max Cancer Laboratories for a period of 02 years;

Therefore, keeping in view of above mentioned facts, M/s Lifemax Cancer Laboratories, Bhagirath Place, Chandni Chowk, Near Chandni Chowk Metro Station, Gate No. 5, New Delhi-110006 is hereby blacklisted for a period of 02 Years from the date of issuance of this order and the EMD(s) submitted by the firm is/are hereby forfeited.

(BY ORDER)

  
21.8.25  
General Manager (Adm.),  
J&K Medical Supplies Corporation Ltd.

No: JKMSCL/GM/DISC/2025-26/ 4833-43

Dated: -08-2025

**Copy to the: -**

1. Secretary to the Government, Health & Medical Education Department, Civil Secretariat, Jammu / Srinagar.
2. All HoDs of Health & Medical Education Department, J&K.
3. Financial Advisor / CAO, J&K Medical Supplies Corporation Ltd. to forfeit the EMD(s) submitted by the firm after seeking details from the concerned section, if not available, the amount equivalent to EMD(s) may be deducted from the payment lying with JKMSCL.
4. General Manager (K), J&K Medical Supplies Corporation Ltd.
5. Dy. General Manager (P&S), J&K Medical Supplies Corporation Ltd.
6. Dy. General Manager (Tend. / Legal), J&K Medical Supplies Corporation Ltd.
7. Medical Officer (QC), J&K Medical Supplies Corporation Ltd.
8. Assistant Legal Remembrancer, J&K Medical Supplies Corporation Ltd.
9. PA to Managing Director, J&K Medical Supplies Corporation Ltd.
10. Assistant Programmer, J&K Medical Supplies Corporation Ltd. to upload the order on official website of JKMSCL.
11. M/s Lifemax Cancer Laboratories, Bhagirath Place, Chandni Chowk, Near Chandni Chowk Metro Station, Gate No. 5, New Delhi-110006
12. Office file.